vs
CURIS INC（CRIS）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
CURIS INC的季度营收约是Arcadia Biosciences, Inc.的1.3倍（$1.1M vs $901.0K），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -66.0%），过去两年Arcadia Biosciences, Inc.的营收复合增速更高（-4.5% vs -26.1%）
Curis Inc.是一家总部位于美国的生物技术企业，专注于创新靶向肿瘤疗法与免疫肿瘤治疗药物的研发及商业化，开发满足肿瘤领域未被满足医疗需求的小分子候选药物，通过与头部制药企业合作为全球患者提供服务。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
CRIS vs RKDA — 直观对比
营收规模更大
CRIS
是对方的1.3倍
$901.0K
营收增速更快
RKDA
高出40.1%
-66.0%
两年增速更快
RKDA
近两年复合增速
-26.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1M | $901.0K |
| 净利润 | — | $-1.3M |
| 毛利率 | — | 21.4% |
| 营业利润率 | — | -152.8% |
| 净利率 | — | -148.3% |
| 营收同比 | -66.0% | -25.8% |
| 净利润同比 | — | 67.1% |
| 每股收益（稀释后） | $1.84 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRISRKDA
| Q4 25 | $1.1M | $901.0K | ||
| Q3 25 | $3.2M | $1.3M | ||
| Q2 25 | $2.7M | $1.5M | ||
| Q1 25 | $2.4M | $1.2M | ||
| Q4 24 | $3.3M | $1.2M | ||
| Q3 24 | $2.9M | $1.5M | ||
| Q2 24 | $2.5M | $1.3M | ||
| Q1 24 | $2.1M | $987.0K |
净利润CRISRKDA
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-7.7M | $856.0K | ||
| Q2 25 | $-8.6M | $-4.5M | ||
| Q1 25 | $-10.6M | $2.6M | ||
| Q4 24 | — | $-4.1M | ||
| Q3 24 | $-10.1M | $-1.6M | ||
| Q2 24 | $-11.8M | $1.1M | ||
| Q1 24 | $-11.9M | $-2.4M |
毛利率CRISRKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率CRISRKDA
| Q4 25 | — | -152.8% | ||
| Q3 25 | -218.0% | -88.5% | ||
| Q2 25 | -300.1% | -34.4% | ||
| Q1 25 | -426.8% | 44.2% | ||
| Q4 24 | -268.9% | -187.7% | ||
| Q3 24 | -360.5% | -114.5% | ||
| Q2 24 | -491.4% | — | ||
| Q1 24 | -597.7% | -160.9% |
净利率CRISRKDA
| Q4 25 | — | -148.3% | ||
| Q3 25 | -243.4% | 65.7% | ||
| Q2 25 | -312.6% | -306.4% | ||
| Q1 25 | -446.1% | 216.6% | ||
| Q4 24 | — | -334.5% | ||
| Q3 24 | -344.3% | -104.9% | ||
| Q2 24 | -463.6% | 81.2% | ||
| Q1 24 | -569.3% | -245.5% |
每股收益（稀释后）CRISRKDA
| Q4 25 | $1.84 | $-0.97 | ||
| Q3 25 | $-0.49 | $0.62 | ||
| Q2 25 | $-0.68 | $-3.26 | ||
| Q1 25 | $-1.25 | $1.90 | ||
| Q4 24 | $-1.10 | $-2.99 | ||
| Q3 24 | $-1.70 | $-1.18 | ||
| Q2 24 | $-2.03 | $0.78 | ||
| Q1 24 | $-2.05 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.1M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.5M | $4.1M |
| 总资产 | $20.0M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRISRKDA
| Q4 25 | $5.1M | $4.6M | ||
| Q3 25 | $9.1M | $5.9M | ||
| Q2 25 | $10.1M | $4.4M | ||
| Q1 25 | $20.3M | $3.2M | ||
| Q4 24 | $20.0M | $4.2M | ||
| Q3 24 | $20.9M | $6.6M | ||
| Q2 24 | $28.4M | $8.1M | ||
| Q1 24 | $40.7M | $8.5M |
股东权益CRISRKDA
| Q4 25 | $5.5M | $4.1M | ||
| Q3 25 | $-14.7M | $5.4M | ||
| Q2 25 | $-14.0M | $4.5M | ||
| Q1 25 | $-6.6M | $8.9M | ||
| Q4 24 | $-6.0M | $6.2M | ||
| Q3 24 | $-8.7M | $10.3M | ||
| Q2 24 | $-694.0K | $11.7M | ||
| Q1 24 | $9.5M | $10.6M |
总资产CRISRKDA
| Q4 25 | $20.0M | $6.5M | ||
| Q3 25 | $27.6M | $8.6M | ||
| Q2 25 | $29.2M | $7.8M | ||
| Q1 25 | $39.3M | $13.0M | ||
| Q4 24 | $41.3M | $13.5M | ||
| Q3 24 | $42.5M | $15.2M | ||
| Q2 24 | $50.4M | $17.4M | ||
| Q1 24 | $62.0M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.4M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CRISRKDA
| Q4 25 | $-6.4M | $-861.0K | ||
| Q3 25 | $-5.6M | $-257.0K | ||
| Q2 25 | $-8.0M | $-2.0M | ||
| Q1 25 | $-7.3M | $-1.6M | ||
| Q4 24 | $-9.3M | $-2.2M | ||
| Q3 24 | $-5.9M | $-1.8M | ||
| Q2 24 | $-11.1M | $-2.5M | ||
| Q1 24 | $-13.2M | $-3.2M |
自由现金流CRISRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-2.5M | ||
| Q1 24 | — | $-3.2M |
自由现金流率CRISRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | — | -326.5% |
资本支出强度CRISRKDA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 1.3% |
现金转化率CRISRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
